Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

about

Low dose naltrexone for induction of remission in Crohn's disease Low dose naltrexone for induction of remission in Crohn's disease The effect of Low Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental before-and-after Prescription Database Study.

P2860

Q24200319-54DDCC77-9154-431A-8579-9447F8A2C0A1 Q24201218-5584D174-B647-48EE-84AE-022EE9A34F98 Q49552898-75C3C397-A2CD-47FC-B260-04571F270EC4

P2860

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

Item

http://www.wikidata.org/entity/Q44330585

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

@en

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

@nl

type

Item

label

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

@en

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

@nl

prefLabel

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

@en

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

@nl

P1476

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

@en

P2093

Ian S Zagon

http://www.w3.org/2001/XMLSchema#string

Patricia J McLaughlin

http://www.w3.org/2001/XMLSchema#string

P2860

Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease

The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation

Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region

Low-dose naltrexone therapy improves active Crohn's disease

Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.

Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function.

Opioid receptors in the gastrointestinal tract.

Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation.

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.

Role of neuropeptides in inflammatory bowel disease.

P304

555-558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1586/EGH.11.62

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51631136

http://www.w3.org/2001/XMLSchema#string

P698

21910569

http://www.w3.org/2001/XMLSchema#string

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

about

P2860

P2860

Targeting opioid signaling in Crohn's disease: new therapeutic pathways.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698